Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Preeclampsia Drugs Market Size Forecast: How Large Could The Market Become By 2030?
The market for preeclampsia drugs experienced swift expansion in recent years, projected to rise from $1.37 billion in 2025 to $1.52 billion in 2026, representing a compound annual growth rate (CAGR) of 10.6%. Historically, this growth has been driven by factors such as insufficient public understanding of preeclampsia management, dependence on conventional treatment methods, a scarcity of sophisticated monitoring tools, inadequate healthcare facilities, and minimal funding directed toward medications for maternal health.
The preeclampsia drugs market is projected to experience substantial expansion in the coming years. By 2030, its value is anticipated to reach $2.37 billion, representing a compound annual growth rate (CAGR) of 11.8%. This projected growth during the forecast period is driven by several factors, including progress in drug formulations, improvements in healthcare infrastructure, a growing preference for outpatient maternal care, the incorporation of digital health technologies, and heightened research and development efforts focused on precision medicine for pregnancy-related conditions. Key developments shaping the forecast period encompass an increasing prevalence of preeclampsia in expectant mothers, the creation of innovative antihypertensive medications, a stronger emphasis on monitoring maternal and fetal health, the expansion of distribution networks through hospital pharmacies and specialty clinics, and the rising use of combination therapies.
Download A Free Sample Report For Comprehensive Market Insights:
Preeclampsia Drugs Market Demand Drivers: What Is Fueling Industry Growth?
The growing prevalence of diabetes in pregnant women is anticipated to accelerate the expansion of the preeclampsia drug market in the foreseeable future. Diabetes is a chronic metabolic disorder marked by elevated levels of blood glucose, or blood sugar. Preeclampsia is a dangerous pregnancy-related complication characterized by high blood pressure and damage to organs. The medication metformin, used to treat preeclampsia, is commonly administered to pregnant women suffering from preterm preeclampsia. For example, in June 2024, the National Health Service, a government body in the UK, reported that in 2023, over half a million (549,000) additional people in England were identified as being at risk for type 2 diabetes. This brought the total number of individuals registered with a GP and diagnosed with non-diabetic hyperglycemia, also known as pre-diabetes, to 3,615,330. This figure represents a substantial rise compared to 3,065,825 in 2022, highlighting an increase of nearly 20%. Consequently, the increasing incidence of diabetes among pregnant women will stimulate the growth of the preeclampsia drug market.
Preeclampsia Drugs Market Segment Analysis Highlighting Growth Areas
The preeclampsia drugs market covered in this report is segmented –
1) By Type: Mild Preeclampsia, Severe Preeclampsia
2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Mild Preeclampsia: Blood Pressure Management
2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy
Preeclampsia Drugs Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the preeclampsia therapeutic landscape are actively pursuing advanced treatment options, including small interfering RNA (siRNA) technologies, designed to target significant unmet medical requirements through innovative modes of action. siRNA experimental therapies fall under a category of drugs that work by silencing or deactivating particular genes responsible for disease onset, enabling a precise therapeutic strategy. A case in point occurred in March 2023 when Comanche Biopharma Corp., a biopharmaceutical enterprise headquartered in the United States, announced that the Food and Drug Administration (FDA) cleared its investigational new drug (IND) application for CBP-4888, a proprietary siRNA agent aimed at managing preeclampsia. Administered subcutaneously, CBP-4888 functions by decreasing the production of soluble fms-like tyrosine kinase-1 (sFLT1) within the placenta. The excessive release of the sFLT1 protein from the placenta into the maternal bloodstream is the fundamental trigger for preeclampsia. By moderating this, CBP-4888 holds the potential to mitigate symptoms like hypertension and organ injury, and could further facilitate the safe prolongation of pregnancy.
Preeclampsia Drugs Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp
Access The Complete Preeclampsia Drugs Market Report:
Preeclampsia Drugs Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in the preeclampsia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model